Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07807111 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Open-Label Study to Evaluate the Safety, Tolerability, and Efficacy of Gene Therapy (SPVN20) in Subjects With Rod-Cone Dystrophy

Study acronym: NYRVANA
StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This open-label, multi-center study is to evaluate the safety, tolerability, and efficacy of escalating doses of a gene therapy called SPVN20 administered via a single intravitreal injection in participants with advanced Rod-Cone Dystrophy.
Trial Details
NCT Number NCT07807111
Lead Sponsor SparingVision
Conditions
(from sponsor)		 Retinitis Pigmentosa (RP), Rod Cone Dystrophy
Related terms Cone-Rod Dystrophies, Eye Diseases, Retinal Degeneration, Retinal Diseases, Retinal Dystrophies, Retinitis Pigmentosa
Enrollment 27 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov